| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NCL.2013.03.010 |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:S073386191300025X?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S073386191300025X?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 23896508 |
| P2093 | author name string | Matthew McCoyd | |
| P2860 | cites work | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 |
| Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 | ||
| Dietary interventions for multiple sclerosis | Q24202428 | ||
| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria | Q24605493 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis | Q28275399 | ||
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | Q28278620 | ||
| Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis | Q28744264 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial | Q30053056 | ||
| Alemtuzumab for multiple sclerosis: who and when to treat? | Q60681801 | ||
| Lethal multiple sclerosis relapse after natalizumab withdrawal | Q61709468 | ||
| Interferon beta in multiple sclerosis | Q70650970 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group | Q70650973 | ||
| Risk stratification and patient counseling for natalizumab in multiple sclerosis | Q83336828 | ||
| Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS | Q83780130 | ||
| Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis | Q84038259 | ||
| Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 | ||
| Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? | Q84968006 | ||
| Birth outcomes in women who have taken leflunomide during pregnancy | Q30419820 | ||
| Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
| Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data | Q31044246 | ||
| Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis | Q32182502 | ||
| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis | Q33381736 | ||
| Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial | Q33400373 | ||
| Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 | ||
| Fingolimod-associated macular edema: incidence, detection, and management | Q34257297 | ||
| New diagnostic criteria for multiple sclerosis: guidelines for research protocols | Q34271601 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Vitamin D intake and incidence of multiple sclerosis | Q34289402 | ||
| Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | Q34300614 | ||
| Multiple sclerosis is not an autoimmune disease | Q34551782 | ||
| Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study | Q34631940 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group | Q34730962 | ||
| Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease | Q35914863 | ||
| Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes | Q36226562 | ||
| Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis | Q36840378 | ||
| Vitamin D and multiple sclerosis: an update | Q37015229 | ||
| Vitamin D as an immune modulator in multiple sclerosis, a review | Q37051712 | ||
| The immunology of multiple sclerosis | Q37078984 | ||
| Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function | Q37180600 | ||
| Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
| Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis | Q37845622 | ||
| The changing face of multiple sclerosis clinical trial populations | Q37889301 | ||
| The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? | Q42573163 | ||
| Pregnancy outcome in women exposed to leflunomide before or during pregnancy | Q43439010 | ||
| Alemtuzumab for multiple sclerosis: a new age of immunotherapy | Q44010478 | ||
| Anti-JC virus antibodies: implications for PML risk stratification | Q45373492 | ||
| Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis | Q45814039 | ||
| Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study | Q46276281 | ||
| MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary | Q48196373 | ||
| Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis | Q48847857 | ||
| Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. | Q48946470 | ||
| Nuclear magnetic resonance imaging of the brain in multiple sclerosis | Q49158364 | ||
| Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? | Q53132815 | ||
| PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS | Q57075856 | ||
| Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis | Q57602087 | ||
| The “Poison Chair” Treatment for Multiple Sclerosis | Q59344890 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 827-845 | |
| P577 | publication date | 2013-05-17 | |
| P1433 | published in | Neurologic Clinics | Q15756619 |
| P1476 | title | Update on therapeutic options for multiple sclerosis | |
| Update on Therapeutic Options for Multiple Sclerosis | |||
| P478 | volume | 31 |
| Q40816256 | Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q38177842 | We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? |
Search more.